Selpercatinib for RET-Altered Thyroid Cancer and MTC: Lori Wirth, MD

In this interview, Lori Wirth, MD, speaks with i3 Health about selpercatinib (RetevmoTM, Eli Lilly), which was recently approved by the FDA for the treatment of patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC), advanced/metastatic RET-mutant medullary thyroid cancer (MTC), and advanced/metastatic RET fusion-positive thyroid cancer. Dr. Wirth, Medical Director of the Center for Head and Neck Cancers at Massachusetts General Hospital and first author of the phase 1/2...
Continue reading

Proton Therapy for Breast Cancer With Rachel B. Jimenez, MD

While conventional radiation therapy can be effective for patients with breast cancer, it carries with it risk of damage to the heart and lungs. Proton beam radiotherapy, a specialized type of external beam radiation that precisely targets a tumor with high doses of radiation while minimizing damage to nearby tissue and critical organs, shows promise as an alternative for some patients. In a phase 2 study published recently in the Journal of Clinical Oncology, a team of researchers at Massachuse...
Continue reading

Proton Beam Radiotherapy for Breast Cancer

A phase 2 trial reports that in patients with nonmetastatic breast cancer requiring postoperative radiation therapy, proton beam radiotherapy has low toxicity, with efficacy comparable to that of conventional radiotherapy. A specialized type of external beam radiation, proton beam radiotherapy precisely targets a tumor with high doses of radiation to kill cancerous cells while minimizing damage to nearby tissue and critical organs such as the heart and lungs. For this safety and efficacy study, ...
Continue reading

Metabolomic Biomarkers Predict Lung Cancer Type, Survival

Investigators are utilizing magnetic resonance spectroscopy to identify metabolomic biomarkers that can predict type, stage, and survival in patients with early-stage lung cancer. Due to lack of early screening methods, lung cancer is commonly not diagnosed until the later stages, resulting in a mortality rate of over 70%. Low-dose spiral computed tomography (LDCT) can detect small lung nodules but is not considered an effective screening tool due to its high cost and radiation hazards. The rese...
Continue reading

Copyright © 2020 Oncology Data Advisor. All rights reserved.